The c-myc oncogene has been implicated in control of cell proliferation and differentiation as well as neoplastic transformation (17, 38) . More recently, overexpression or inappropriate time of expression of the c-myc gene has been found to promote apoptosis. Askew and coworkers observed that addition of a vector expressing c-Myc protein accelerated apoptosis following interleukin-3 deprivation of the 32D interleukin-3-dependent myeloid cell line (6) . Similarly, Evan et al. (22) found that transfection of 3T3 fibroblast cells with c-myc expression vectors led to enhanced levels of apoptosis upon growth arrest either by serum or isoleucine deprivation or by a thymidine block. The interaction of c-Myc with its binding partner Max (Myc-associated factor X) (12, 13) was found to be necessary to promote apoptosis (3) . These findings have been further extended by using c-myc antisense oligonucleotides. Green and coworkers have shown that addition of these oligonucleotides to immature T cells and some T-cell hybridomas inhibited c-myc expression and prevented T-cell receptormediated apoptosis (48) . Together these results strongly suggest that inappropriate overexpression of c-myc promotes apoptosis in some cell systems.
The WEHI 231 lymphoma cell line has been characterized as an immature B cell on the basis of surface markers and biological properties (43, 45) . Growth of these cells can be arrested within 24 h by interaction with an antibody against the expressed surface immunoglobulin M (IgM) chains (14, 45) . Boyd and Schrader (14) proposed this system as a model for self-induced B-cell tolerance. In support of this hypothesis, it was demonstrated that anti-IgM treatment causes apoptosis of WEHI 231 cells within 18 h (10, 27) . Treatment of WEHI 231 cells with anti-IgM antiserum results in dramatic changes in c-myc expression. As we first showed several years ago, an initial 5-to 10-fold increase in c-myc mRNA levels between the first and second hours after treatment is followed by a rapid decline in c-myc expression (40) . By 6 to 8 h of treatment, c-myc RNA and protein levels fall well below control values (36, 39) . Several lines of evidence suggest that it is the drop in c-myc expression following anti-Ig treatment that results in apoptosis of WEHI 231 cells, in contrast to the findings discussed above. Binding of an introduced ␦ heavy chain (WEHI-␦) with an anti-IgD antibody resulted in an increase in c-myc RNA levels similar to that seen upon anti-treatment but not in the subsequent drop below the control levels (54) . These cells do not cease proliferation, and apoptosis does not occur (54) . Similar results were obtained by Ales-Martinez and coworkers with another B-cell line, CH33, also transfected to express IgD (2) . Furthermore, mutants of WEHI 231 resistant to anti-IgM-induced apoptosis display only a transient increase in c-myc RNA levels following anti-Ig treatment (29) , whereas treatment of WEHI 231 cells with transforming growth factor ␤ (TGF-␤) induces a drop in levels of c-myc expression and subsequently apoptosis (56) . More recently, Fischer et al. (23) found that addition of an antisense oligonucleotide specific for c-myc prevented apoptosis of WEHI 231 cells but surprisingly led to stabilization of c-myc expression. Although the mechanism for this stabilization was not determined, these results also suggest that it is the drop in c-myc expression to levels below those seen in exponentially growing cells that signals apoptosis.
Recently we have demonstrated that the nuclear factor B (NF-B)/Rel family of transcription factors plays a major role in the control of c-myc gene expression following anti-Ig treatment of WEHI 231 cells (35) . The murine c-myc gene contains two functional NF-B elements, which we termed the upstream regulatory element (URE) and the internal regulatory element (IRE) (20, 33) . Exponentially growing WEHI 231 cells express a large amount of nuclear NF-B/Rel factors, in part because of the rapid rate of turnover in these cells of the specific inhibitory protein IB␣ (42, 46) . We have recently demonstrated that changes in the binding of NF-B/Rel factors mediate signals leading to both the increase and the decrease in c-myc expression following anti-Ig treatment (35) . To test directly whether it is the increase or the decrease in c-myc expression that promotes apoptosis of WEHI 231 cells, here we have used the protease inhibitor N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), which inhibits IB␣ turnover in WEHI 231 cells (28, 42) , to modulate NF-B/Rel activation and binding. Addition of TPCK led to a rapid drop in levels of NF-B/Rel binding that could not be overcome by anti-Ig treatment. TPCK blocked the increase in c-myc expression normally resulting from anti-Ig treatment and, when added alone, caused a decrease in c-myc expression. TPCK induced apoptosis when added alone and failed to block apoptosis mediated by anti-Ig. Ectopic expression of c-Myc decreased levels of apoptosis induced by TPCK or anti-Ig treatment. Furthermore, to reduce functional c-Myc levels, cells were microinjected with the Max binding partner Mad1 and apoptosis was induced. These results indicate that the drop in c-myc expression following TPCK treatment plays a pivotal role in the induction of cell death in the WEHI 231 B-cell line.
MATERIALS AND METHODS
Culture and treatment conditions. WEHI 231 cells were maintained in Dulbecco modified Eagle medium supplemented with 10% fetal calf serum, 0.35% glucose, 0.058% glutamine, nonessential amino acids (Gibco Laboratories, Grand Island, N.Y.), 100 U of penicillin per ml, 100 g of streptomycin per ml, and 50 M ␤-mercaptoethanol, as described previously (35) . Prior to treatment, cells were diluted to a density of 4 ϫ 10 5 cells per ml with fresh warm medium and allowed to incubate for a minimum of 4 to 5 h. Cell cultures were incubated with 10 to 25 M TPCK (Sigma Chemical Co., St. Louis, Mo.) for the indicated times. Cells were treated with 1:1,000 dilution of anti-heavy chain antibody (Cappel Laboratories, Cochranville, Pa., or Calbiochem, La Jolla, Calif.) for 1 to 52 h.
Electrophoretic mobility shift analysis. Crude nuclear extracts were prepared by the method of Strauss and Varshavsky (53) . The 221-bp fragment of DNA spanning BglII to AccI, including bp Ϫ1139 to Ϫ921 relative to the P1 promoter of the murine c-myc gene, was subcloned into pUC19. This DNA, termed fragment A previously (20) , includes the URE B element, which is located 1,101 to 1,081 bp upstream of the P1 promoter. DNA fragments were end labelled with the large fragment of Escherichia coli DNA polymerase I (New England Biolabs) and ␣-32 P-deoxynucleoside triphosphates (New England Nuclear). The electrophoretic mobility shift assay (EMSA) was performed as follows. Each 32 P-labelled fragment (25,000 cpm; approximately 2 ng) and 3.5 g of nuclear extract were mixed in 70 mM NaCl-10 mM HEPES (N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid; pH 7.5)-1 mM EDTA-1 mM dithiothreitol-0.1% Triton X-100-4% (vol/vol) glycerol-5 g of poly(dI-dC) ⅐ poly(dI-dC) copolymer in a final volume of 25 l. This mixture was incubated for 30 min at 22ЊC. Gels were electrophoresed at 11 V/cm in a 4 or 4.5% polyacrylamide gel with TAE running buffer (6.7 mM Tris-HCl [pH 7.5], 3.3 mM sodium acetate, 1 mM EDTA), dried, and subjected to autoradiography.
Plasmids and transfection. The p1.6 Bgl chloramphenicol acetyltransferase (CAT) construct contains bp Ϫ1141 to ϩ513 of the murine c-myc gene, containing promoter-upstream-exon 1 sequences, including both the NF-B upstream and internal regulatory elements (21) . The double-mutant p1.6 Bgl construct (dm p1.6 Bgl), prepared by the double-primer site-directed mutagenesis method, contains two G-to-C transversions in both the URE and the IRE, preventing Rel factor binding and transactivation (21, 34) .
For transient transfections, exponentially growing WEHI 231 cells were washed once with medium and resuspended in Dulbecco modified Eagle medium supplemented with 20% fetal calf serum at a concentration of 20 ϫ 10 6 cells per ml. Cells (250 l) were preincubated on ice for 10 min with DNA (40 g). Cells were transfected by electroporation at 240 V and 960 F using a Gene Pulser (Bio-Rad Laboratories). Following incubation on ice for 5 min, the cell suspension was mixed with 1.75 ml of complete medium and incubated for 10 min at room temperature. The suspensions were transferred to petri dishes, and some were further treated with TPCK and/or anti-Ig. Following incubation at 37ЊC for 8 h, cells were harvested and the resulting extracts were normalized for total protein content by using the Bio-Rad protein quantitation kit. Equal amounts of lysates were assayed in duplicate for CAT activity, as we have described previously (35) . Standard deviations were obtained by Student's t test.
Linearized vector DNA was used to isolate stable transfectants expressing the pRc-CMV-myc vector (25) . DNA (30 g) was incubated with XbaI, and then the enzyme was inactivated by incubation for 5 min at 68ЊC. Alternatively, 30 g of pSV2-neo was used. For preparation of the pM21 c-myc expression vector (9), stable transfectants were prepared by using 40 g of pM21 and 2 g of pSV2-neo. Electroporation was performed essentially as described above. After 24 to 48 h, 1.2 mg of G418 (Gibco Laboratories) per ml was added to the culture medium and selective growth conditions were maintained for approximately 2 weeks. Clones were isolated by limiting dilution.
RNA and protein analysis. Total RNA was isolated with TRI reagent (Mo- (5 g) were used in electrophoretic mobility shift analysis with a DNA fragment containing the upstream NF-B element from the murine c-myc gene. The specificities of the changes were confirmed by mobility shift analysis with an AP-1 oligonucleotide (data not shown). Identities of most of the bands, labelled 1 through 6, were determined previously by using specific antibody reagents (35) and are as follows: band 1, p50 homodimer; band 2, p50-c-Rel; band 3, p50-RelA; band 4, p50 and unidentified subunit; and band 5, c-Rel homodimer. Band 6 was unidentified.
FIG. 2. TPCK inhibits transcription of the c-myc promoter. WEHI 231 cells were transfected with 40 g of DNA of a p1.6 Bgl wild-type CAT construct or a double-mutant (dm) construct in which both NF-B elements contain two Gto-C conversions such that Rel factor binding is prevented. Following transfection, cultures were divided and treated with anti-Ig in the presence or absence of 10 M TPCK, as indicated. Alternatively, cells were treated with 10 M TPCK alone. Extracts were prepared after 7 h and assayed for CAT activity. The data are presented relative to untreated wild-type p1.6 Bgl CAT activity, which is set at 100%. Standard deviations were obtained by Student's t test. lecular Research Center, Inc., Cincinnati, Ohio) according to the manufacturer's protocol. Samples of RNA (15 g per lane) were analyzed by Northern (RNA) blotting, as we have described previously (36) . Probes used included the mouse c-myc cDNA clone pM-c-myc54 (51) and a glyceraldehyde-3-phosphate dehydrogenase clone (19) .
Nuclear proteins were isolated by using radioimmunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 7.5], 150 mM NaCl, 1% Nonidet P-40, 0.1% sodium dodecyl sulfate [SDS], 1% sodium sarcosyl) as described previously (4) . The protease inhibitors leupeptin (10 g/ml), phenylmethylsulfonyl fluoride (0.5 mM), and dithiothreitol (1 mM), which were prepared as fresh stocks, were added to buffers just prior to use. The nuclear suspension was sheared and the nuclear debris was removed via centrifugation, and the supernatant was subjected to SDS-10% PAGE analysis with Rainbow markers (Amersham) and processed for Western blotting (immunoblotting), as we have described previously (39) except that membranes were developed with a Du Pont chemiluminescence kit (NEN). An affinity-purified antibody (50-23) against whole mouse c-Myc protein (kindly provided by S. Hann, Vanderbilt University, Nashville, Tenn.) was used at a 1:1,000 dilution.
Apoptosis assays. For analysis of DNA laddering, about 10 6 cells were used according to the procedure of Smith et al. (50) . Briefly, control or treated cells were collected by centrifugation and washed in cold phosphate-buffered saline (PBS) twice. Pellets were then resuspended in 20 l of lysis buffer containing 10 M EDTA, 50 mM Tris-HCl (pH 8.0), 0.5% (wt/vol) sodium laurylsarcosine (Sigma), and 0.5 mg of proteinase K (Boehringer Mannheim GmbH, Mannheim, Germany) per ml, and the mixture was incubated at 50ЊC for 1.5 h. Then 10 l of RNase A (0.5 mg/ml) was added, and the incubation was continued for 1 h. Samples were then heated to 70ЊC for 10 min, quickly chilled, and mixed with 10 l of loading buffer consisting of 1% low-melting-point (LMP) agarose (Bethesda Research Laboratories, Gaithersburg, Md.), 40% (wt/vol) sucrose, and 0.25% (wt/vol) bromophenol blue prior to electrophoresis in a 1.5% agarose gel. The 123 ladder DNA (Gibco) was used as a marker. Electrophoresis was performed overnight at 20 V in 1ϫ TAE buffer.
For the fluorescence assay for apoptosis, quantitation of apoptotic cells was performed as previously described (26, 30) . Briefly, cells were washed in cold PBS, pelleted, and resuspended in 1.5 ml of hypotonic fluorochrome solution containing 5.0 g of propidium iodide (PI) (Sigma Chemical Co.) per ml, 1% sodium citrate, and 0.1% Triton X-100 (Sigma). Treated cells were analyzed on a Becton Dickinson FACScan flow cytometer. Cells undergoing DNA fragmentation and apoptosis were shown to be weaker in PI fluorescence than those in the typical G 0 /G 1 cell cycle.
For trypan blue exclusion assays, cells were incubated with 0.2% trypan blue Mad1-glutathione S-transferase (GST) protein (8) or control GST protein was prepared as we have described previously (4) and concentrated by spin dialysis using Ultrafree CL filters (Millipore, Marlborough, Mass.) to a concentration of 1 mg/ml for microinjection. Alternatively, 1 mg of Mad1 expression vector (pMAD.VZ1; kindly provided by R. DePinho [Albert Einstein College of Medicine, Bronx, N.Y.]) per ml was microinjected in the absence or presence of a pM21 c-Myc expression vector (1 mg/ml). Following microinjection, cloning rings were placed over the microinjected areas and the medium was replaced with 10% FBS-Dulbecco modified Eagle medium. After 30 min of incubation at 37ЊC, cells that had survived the microinjection were detached from the tissue culture plates by gentle trituration, transferred to multiwell plates, and incubated at 37ЊC. After 20 h, 1/10 of a volume of a trypan blue solution (0.04% final concentration) was added to each well, cells were incubated for 15 min, and viable cell counts were obtained. Alternatively, cells were fixed at 4.5 h after microinjection in 3.7% formaldehyde in 0.2ϫ PBS for 10 min at room temperature and then transferred to a glass slide. After air drying, cells were rehydrated in 1ϫ PBS and stained in 5 g of PI per ml for 15 min at room temperature. After mounting in 90% glycerol-PBS, cells were viewed in a Nikon Optiphot microscope and fluorescent images were recorded at a magnification of ϫ200 by using TMAX (ASA 3200) film.
RESULTS
TPCK reduces NF-B/Rel factor binding activity. To determine whether treatment with the protease inhibitor TPCK, which stabilizes IB␣ in WEHI 231 (28, 42 ; also data not shown) down-regulates NF-B/Rel binding, cells were incubated in the absence or presence of 25 M TPCK for 0.5 h and then subsequently treated with anti-Ig for 1 h. Alternatively, cells were incubated in TPCK alone for 1 or 2.5 h. Nuclear extracts were prepared, and an EMSA using the 221-bp BglIIto-AccI DNA fragment upstream of the c-myc promoter, which contains the upstream NF-B element, was performed (Fig. 1) . Extracts from untreated exponentially growing WEHI 231 cell nuclei contain six distinguishable specific NF-B/Rel complexes (20, 35 ) (see the legend to Fig. 1 ). Treatment with TPCK alone significantly decreased the levels of NF-B/Rel complexes 2 through 6 by 1 h, and the levels continued to decrease with time. TPCK significantly reduced formation of RelA-and c-Rel-containing complexes, including p50-RelA (band 3), p50-c-Rel (band 2), and c-Rel homodimers (band 5). In contrast, formation of p50 homodimer (band 1) was only modestly affected. Thus, TPCK treatment resulted in decreased formation of complexes that transactivate either modestly (p50-c-Rel) or potently (p50-RelA), but it has less effect on p50 homodimers which are unable to transactivate c-myc in vivo (34, 35) . Furthermore, the presence of TPCK caused a TPCK suppresses the transcriptional activity of the c-myc promoter. To monitor the effects of TPCK treatment on c-myc gene transcription, transfection analysis was performed. The p1.6 Bgl construct consists of bp Ϫ1141 to ϩ513 of the murine c-myc gene, containing promoter-upstream-exon 1 sequences, including both the upstream and internal NF-B elements, linked to the CAT reporter gene (21) . The double-mutant p1.6
Bgl construct (dm p1.6 Bgl) contains two G-to-C transversions in both the URE and the IRE. Following introduction of these constructs into WEHI 231 cells via electroporation, cells were incubated for 7 h with anti-Ig either in the absence or in the presence of TPCK (10 M) or with TPCK alone (Fig. 2) . Anti-Ig treatment induced the CAT activity of the wild-type p1.6 Bgl construct, but not the mutant construct, approximately 2.5-fold, consistent with previous findings (35) . TPCK treatment alone decreased activity of the wild-type construct 6.6-fold compared with the control. The levels were reduced to that of dm p1. alone for 2 h or with anti-Ig alone for 1.5 h and RNA was isolated. Northern blot analysis demonstrated that TPCK blocked the five-to eightfold induction of c-myc RNA normally resulting from treatment with anti-Ig for 1.5 h (Fig. 3) . No change in the basal level of c-myc RNA was noted within 0.5 h of treatment with TPCK alone, whereas a decline was observed over the subsequent 90-min period. These kinetics are consistent with the time necessary to see the drop in mRNA expression following the decline in transcription due to inhibition of NF-B/Rel complex formation. Equal RNA loading and integrity was confirmed by rehybridization with a probe for the housekeeping gene coding for glyceraldehyde-3-phosphate dehydrogenase (Fig. 3) . Thus, TPCK treatment of WEHI 231 cells suppressed basal c-myc expression and prevented the normal activation of c-myc mRNA by anti-Ig treatment.
TPCK induces apoptosis of WEHI 231 cells. Having confirmed that TPCK prevents the normal increase in c-myc expression upon treatment with anti-Ig and induces a reduction in basal levels of expression of this oncogene when added alone, we tested the effects of TPCK on cell death. Cells that had been pretreated with 0, 10, 25, or 50 M TPCK for 30 min were subjected to 13 h of anti-Ig treatment. Alternatively, cultures were treated with similar doses of TPCK alone for 13.5 h. Apoptosis was measured by DNA fragmentation assay (50) . Suppression of the anti-Ig-mediated induction of NF-B/ Rel activity and c-myc RNA levels in WEHI 231 cells due to TPCK treatment failed to prevent apoptosis (Fig. 4) . In fact, pretreatment with 10 or 25 M TPCK appeared to enhance the extent of DNA fragmentation. Furthermore, incubation of WEHI 231 cells with 10 M TPCK alone induced as much DNA laddering as is observed normally following a similar time of anti-Ig treatment, and more extensive fragmentation was observed following treatment with 25 M TPCK. DNA fragmentation was detectable by about 4 h following treatment with 25 M TPCK (data not shown). Thus, induction of apoptosis in WEHI 231 cells correlates with the drop in c-myc RNA levels mediated by TPCK treatment.
TPCK decreases c-Myc protein levels. To confirm that TPCK treatment indeed mediated a drop in c-Myc protein levels comparable to its effects on c-myc mRNA expression, immunoblot analysis was performed. Nuclear extracts were prepared from WEHI 231 cells in exponential growth and after 1, 2, 4, 6, or 8 h of TPCK treatment. As seen in Fig. 5A , a drop in the level of c-Myc protein in the nucleus was observed within 2 h and levels continued to decline for up to 8 h of treatment. These findings are consistent with the kinetics of the c-myc RNA profiles obtained as described above and confirm that TPCK treatment causes a significant drop in c-Myc protein levels that correlates with the induction of apoptosis.
Ectopic expression of c-Myc attenuates apoptosis of WEHI 231 cells induced by TPCK.
Since the drop in c-myc expression mediated by TPCK correlated with activation-induced cell death, we next sought to determine whether ectopic expression of c-Myc protein in WEHI 231 cells would prevent apoptosis. Stable transfectants were made with the c-myc expression vector pM21 (9), which is driven by the Moloney murine leukemia virus long terminal repeat (52) , and clonal lines were isolated by limiting dilution. As controls, pSV2neo-transfected clones were similarly prepared. Twenty pM21-transfected clones and six pSV2neo-transfected clones were isolated. These were as- transfected with control pSV2neo (S10-and S12-WEHI 231) exhibited significant levels of apoptosis (34% Ϯ 3% when results obtained with each clone were averaged). In contrast, nine clones (i.e., the pM21 clones P2-, P4, P8-, P14-, P17-, P24-, P25-, P35-, and P36-WEHI 231) stably expressing c-Myc were markedly less sensitive to TPCK, with only 12% Ϯ 3% of the cells affected by the treatment. pSV2neo-and pM21 expression vector-transfected cells not treated with TPCK showed 2 and 3% apoptosis, respectively. A more complete time course of the effects of TPCK on cell viability was performed. Two of the lines expressing c-Myc, i.e., P14-and P17-WEHI 231, and two pSV2neo-transfected lines (S8-and S10-WEHI 231) were treated in triplicate with 25 M TPCK, and cell viability was monitored by the MTS dye conversion assay (Fig. 9) . As expected, anti-Ig treatment of parental WEHI 231 cells results in an initial increase in c-Myc protein levels followed by a decline (Fig.  9A) , consistent with the changes in the levels of c-myc RNA (35, 40) . In the two c-myc-transfected lines, extensive expression of c-Myc protein was noted even after 14 h, whereas the S8-WEHI 231 line displayed a drop similar to that in the parental line (Fig. 9B) . To examine the time course of the effects of anti-Ig, cell death was monitored over a 48-h period by using conversion of MTS to its formazan product (Fig.  10A) . The two pSV2neo-transfected lines displayed extensive loss of cell viability by 24 h of anti-Ig treatment. The time course of the effects of anti-Ig on cell death is consistent with previous findings (10, 14, 27) . In contrast, significantly less cell death was observed following anti-Ig treatment of two myctransfected lines, with approximately 90% viable cells remaining after 48 h of treatment of the P14-and P17-WEHI 231 lines (Fig. 10A) . Trypan blue analysis of similarly treated cell cultures, carried out over a 52-h time frame, demonstrated greater than 70% loss of cell viability for the pSV2neo (S10-WEHI 231) line compared with less than 30% for the P17-WEHI 231 c-myc-transfected line (Fig. 10B) . Furthermore, proliferation of these cells was clearly evident after 52 h of anti-Ig treatment (Fig. 10C) . In Fig. 10D , a representative comparison of trypan blue-stained cultures of control (S8-WEHI 231) and c-myc-expressing (P17-WEHI 231) cells treated with anti-Ig for 24 h, depicting the effects of c-Myc expression on cell survival, is given. Thus, ectopic expression of c-Myc affords WEHI 231 cells substantial protection from antiIg-mediated apoptosis.
TPCK treatment of CMV promoter-myc expression vector stable WEHI 231 transfectants results in a dramatic decline in c-Myc levels and more rapid induction of apoptosis. Stable transfectants of WEHI 231 cells were also prepared by using the pRc-CMV-myc expression vector. In this construct, Myc 2 protein, the predominant form initiated at the AUG codon start site, is expressed under the control of the cytomegalovirus (CMV) promoter. A total of 20 pRc-CMV-myc-expressing clones were selected with the antibiotic G418. In addition, five clones containing the pSV2neo parental vector were similarly isolated. Cells were incubated in the presence or absence of 25 M TPCK and analyzed for expression of c-Myc and for induction of apoptosis. Expression of pRc-CMV-myc led to enhanced expression of c-Myc protein as indicated by Western blotting (Fig. 11A and data not shown) . The level of c-Myc protein was dramatically inhibited by TPCK treatment. The extent of the drop was more complete than that in control cells. This result is consistent with the notion that the CMV promoter, which contains five full and six partial NF-B elements (16) , is driven predominantly by Rel factor binding in WEHI 231 cells, and upon inhibition of NF-B/Rel binding by TPCK treatment the level of activity of this promoter dropped dramatically. When the pRc-CMV-myc clones of these cells were subjected to analysis for apoptosis, the induction of cell death following TPCK treatment appeared accelerated. For example, Fig. 11B shows a typical comparison for clones transfected with pRc-CMV-myc (M4-WEHI 231) and clones transfected with the pSV2neo control (S5-WEHI 231) using trypan blue exclu- sion. More extensive cell death was noted within 2.5 h in the CMV-myc-transfected line than in control cells. Similar results were seen by DNA ladder formation (data not shown), although this method is less quantitative. These results suggest that the more precipitous decline of the elevated initial levels of c-Myc protein in the lines transfected with pRc-CMV-myc resulted in a more dramatic induction of apoptosis. Microinjection of Mad1 induces apoptosis. The data presented above indicated that expression of c-myc can curtail apoptosis induced by TPCK or anti-Ig. To determine whether down-regulation of c-myc is sufficient to induce apoptosis of WEHI 231 cells, we microinjected agents known to specifically counteract Myc function. The effects of introduction of Mad1, a specific binding partner of Max (8), were monitored. Max, which potentiates the binding activity of Myc-Max heterodimers through its basic region, has been shown to play a central role in functional activity of c-Myc (3, 8) . Introduced Mad1 has been found to compete with c-Myc for interaction with Max and thus to serve as a competitive inhibitor of functional c-Myc (7). Microinjection of Mad1-GST protein significantly increased death of WEHI 231 cells, as judged by trypan blue positive staining ( Fig. 12A and Table 1 ). In contrast, microinjection of control GST protein had little effect on induction of cell death. Apoptosis of these cells was confirmed by the appearance of condensed chromatin following microinjection of Mad1-GST (Fig. 12C , bottom panel) compared with microinjection of GST alone (Fig. 12C, upper panel) , as visualized by PI staining 4.5 h after microinjection. In order to verify the specificity of this effect, we microinjected a Mad1 expression vector in the presence or absence of the Myc expression vector pM21. Microinjection of Mad1 expression vector similarly induced cell death, indicating that apoptosis was not due to general toxicity of the protein preparation (Fig.  12B) . The level of cell death was reduced significantly upon comicroinjection of a c-myc expression vector but not of control Bluescript vector DNA. These results indicate that the down-regulation of functional c-Myc is sufficient to induce apoptosis of WEHI 231 cells.
DISCUSSION
The vector was used, the enhanced drop in c-Myc expression was found to correlate with a more rapid induction of apoptosis. To confirm this role, we employed microinjection analysis. Microinjection of either Mad1 protein or a vector expressing Mad1 induced apoptosis of WEHI 231 cells directly. Consistent with these conclusions, previous results had indicated a correlation between the drop in c-myc levels and the induction of apoptosis in WEHI 231 and other B-cell lines at a similar stage of development, i.e., CH31 or CH33. For example, treatments, such as anti-Ig and TGF-␤1 (10, 27, 36, 40, 56) , that result in decreased c-myc expression lead to the induction of apoptosis. In contrast, agents that induce c-myc expression but fail to cause the subsequent drop, including anti-IgD and lipopolysaccharide, all fail to induce apoptosis (14, 29, 54, 56) . Furthermore, addition of an antisense c-myc oligonucleotide that surprisingly stabilized c-Myc protein expression in WEHI 231 and CH31 cells prevented apoptosis induced by anti-Ig or TGF-␤1 treatment (23; also data not shown). We have recently found that the T-cell CD40 ligand, which protects against antiIgM-induced apoptosis of WEHI 231 cells and leads to continued cell growth and viability (55) , causes maintenance of NF-B and c-myc expression (47) . Our recent results also show that ectopic c-myc expression protects against TGF-␤1-mediated apoptosis of WEHI 231 cells (5) . Taking these results together with the findings presented here, we conclude that the drop in functional Myc leads to physiologic death of WEHI 231 B cells.
In contrast to these results, evidence indicating that overexpression of c-myc promotes apoptosis, in particular following loss of a growth promoting signal, has accumulated. Thus, growth factor deprivation of fibroblasts, myeloid cells, or smooth muscle cells overexpressing c-Myc, via either an estrogen-inducible estrogen receptor fusion protein or an ectopic c-myc expression vector, induced accelerated apoptosis (6, 11, 22) . Furthermore, interference with T-cell receptor-mediated upregulation of c-myc by the use of c-myc antisense oligonucleotides ablated apoptosis (48) . Similarly, antisense oligonucleotides against c-myc rendered fibrosarcoma cells resistant to tumor necrosis factor alpha mediated cell death (31) . These findings support a role for c-myc in promoting apoptosis, although the exact mechanism for c-Myc action in these diverse systems is unclear. In fibroblasts, the interaction of c-Myc with Max appears obligatory to promote the induction of apoptosis (3). In the WEHI 231 system, overexpression of Mad1, which competes for Max binding and negatively regulates c-Myc (7, 8) , induced apoptosis. These findings demonstrate a direct role for Mad1, and therefore Max, in apoptosis of B cells, although in this case the reduction in the level of c-Myc activity correlates with induction of cell death. Interestingly, we have recently found that TPCK and TGF-␤1 treatments of WEHI 231 cells lead to activation of Mad1 expression that precedes apoptosis, suggesting that this protein plays a role in B-cell death under physiologic circumstances (58) .
Germinal centers are active sites of normal B-lymphocyte differentiation; hypermutation and proliferation of activated B cells occurs in these microenvironments following antigen immunization (18, 32) . Ig gene mutation can also lead to formation of self-reactive antigens. It has been suggested that these B lymphocytes are eliminated within the germinal centers, and recent evidence indicates that soluble antigen causes enhanced apoptosis of germinal-center B cells (44, 49) . Interestingly, CD40 ligand has been found to override apoptosis in germinal centers, raising the intriguing possibility that NF-B/Rel and c-Myc proteins play similar roles in apoptosis within the germinal center.
Bcl-X L expression can result in survival of WEHI 231 from anti-Ig-induced physiologic cell death (24) . Surprisingly, recent evidence has indicated that in this case Bcl-X L fails to prevent arrest of cells in the G 1 /S phase (41) . These findings suggest that anti-Ig treatment induces a change in signalling apart from those responsible for the arrest of the cell cycle that induces apoptosis of WEHI 231 cells and that Bcl-X L compensates for this alteration, thereby overriding induction of apoptosis of this line. Consistent with these observations, Bcl-X L also ablates TPCK-mediated induction of apoptosis of WEHI 231 cells but fails to prevent the drop in c-Myc protein expression (data not shown).
The serine proteinase inhibitor TPCK has been demonstrated to be a potent, specific inhibitor of NF-B/Rel activity (28) . It acts via stabilization of the normally labile IB␣ protein, preventing its decay. For example, in the presence of TPCK the short half-life of IB␣ protein in WEHI 231 cells (20 min) is significantly lengthened (to Ͼ1.5 h) (42; also data not shown). The ability to modulate IB␣ and thus NF-B is specific to TPCK. Other similar proteinases do not have such an activity. Thus, aprotinin, leupeptin, and phenylmethylsulfonyl fluoride have not been found to affect NF-B binding, and these inhibitors failed to induce apoptosis of WEHI 231 cells (data not shown). In addition, we similarly tested the effects of TPCK treatment on NIH 3T3 fibroblasts. NIH 3T3 cells do not appear to express significant levels of NF-B/Rel (34) . Treatment of these cells with 25 M TPCK only slightly affected their growth, while higher doses, e.g., 50 to 100 M TPCK, caused arrest of cell growth but not apoptosis (59) . These findings suggest that it is the effects of TPCK on NF-B/Rel and thus on c-myc that lead to the apoptosis of these B lymphocytes (59) . The observation that anti-Ig treatment of WEHI 231 cells results in a rapid decline in NF-B/Rel binding (35) , and thus in c-myc expression, rather than activation as has been found for splenic B lymphocytes (15, 37) is likely the result of developmental control that is also responsible for the induction of apoptosis of these immature B cells. These findings, therefore, implicate not only NF-B/Rel factors, as has been found by other groups (1, 57) , but also members of the IB family of inhibitory proteins that regulate their expression as potential early mediators of signals controlling apoptosis in these B cells.
ACKNOWLEDGMENTS
We thank J. Cleveland, R. DePinho, R. Eisenman, and S. Hann for generously providing cloned DNAs and antibody preparations and P. 
